Tumour Regression after Intravenous Administration of Novel Targeted Anti-cancer Therapeutic SystemsTuesday, 19 March 2013 at 09:30  Add to Calendar ▼2013-03-19 09:30:002013-03-19 10:30:00Europe/LondonTumour Regression after Intravenous Administration of Novel Targeted Anti-cancer Therapeutic SystemsSELECTBIOenquiries@selectbiosciences.comThe possibility of using genes as medicines to treat cancer is limited by the lack of efficacious delivery systems able to selectively deliver genes to tumours. We demonstrated that the intravenous administration of a tumour-targeted dendriplex led to tumour disappearance of 90% of the tested tumours over one month. |
Add to Calendar ▼2013-03-19 00:00:002013-03-20 00:00:00Europe/LondonFormulation and SolubilitySELECTBIOenquiries@selectbiosciences.com
